Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Operating Expenses (2023 - 2025)

Immunome's Operating Expenses history spans 3 years, with the latest figure at $72.9 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 14.99% year-over-year to $72.9 million; the TTM value through Dec 2025 reached $231.1 million, down 26.61%, while the annual FY2025 figure was $231.1 million, 26.61% down from the prior year.
  • Operating Expenses reached $72.9 million in Q4 2025 per IMNM's latest filing, up from $60.1 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $133.3 million in Q1 2024 to a low of $6.8 million in Q1 2023.
  • Average Operating Expenses over 3 years is $55.8 million, with a median of $52.0 million recorded in 2024.
  • Peak YoY movement for Operating Expenses: soared 1850.67% in 2024, then plummeted 64.33% in 2025.
  • A 3-year view of Operating Expenses shows it stood at $98.5 million in 2023, then fell by 12.97% to $85.7 million in 2024, then fell by 14.99% to $72.9 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Operating Expenses are $72.9 million (Q4 2025), $60.1 million (Q3 2025), and $50.5 million (Q2 2025).